I LOVE this deal. It is 'one with the lot'.
Those who saw the potential value of 'investing' in this company can now sit back and enjoy the prospect of a major Aus/NZ company unfold over the coming years.
To me, reading between the lines, this deal suggests that the confidence of those close to both drugs must be sky high. Going forward, there is now minimal risk involved.
Hearty congratulations to both companies. May they have an ongoing harmonious, profitable and (most importantly) highly successful neuro drug treatment future.
Ann: Neuren and Acadia expand global partnership for trofinetide, page-17
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $14.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.23 | 3278 | 1 |
View Market Depth
| Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |